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Abstract
Background: Local myogenesis, neoangiogenesis and homing of progenitor cells from the bone
marrow appear to contribute to repair of the infarcted myocardium. Implantation into heart tissues
of autologous skeletal myoblasts has been associated with improved contractile function in animal
models and in humans with acute myocardial ischemia. Since heart infarction is most prevalent in
individuals of over 40 years of age, we tested whether culture methods available in our laboratory
were adequate to obtain sufficient numbers of differentiated skeletal myoblasts from muscle biopsy
specimens obtained from patients aged 41 to 91.
Methods and results: No matter of donor age, differentiated skeletal muscle cells could be
produced in vitro in amounts adequate for cellular therapy (≥300 millions). Using desmin as a
cytoplasmic marker, about 50% cultured cells were differentiated along myogenic lineages and
expressed proteins proper of skeletal muscle (myosin type I and II, actin, actinin, spectrin and
dystrophin). Cytogenetic alterations were not detected in cultured muscle cells that had undergone
at least 10 population doublings. Molecular methods employed for the screening of persistent viral
infections evidenced that HCV failed to replicate in muscle cells cultured from one patient with
chronic HCV infection.
Conclusion: The proposed culture methods appear to hold promise for aged patients not only in
the field of cardiovascular medicine, but also in the urologic and orthopedic fields.
Background
The concept of therapeutic implantation of autologous
cells capable of replicating and differentiating into spe-
cialized progeny has generated great interest. This
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cardiovascular medicine for the regeneration of the inf-
arcted heart [1]. Skeletal muscle has an outstanding ability
to respond to the requirements of growth, remodeling,
physical activity, and injury. Since adult myofibers are ter-
minally differentiated, the regeneration of skeletal muscle
is mostly dependent on a population of resident cells
termed satellite cells (SC). These cells lie beneath the basal
lamina, but above the plasma membrane of myofibers
[2]. When physiologically required, SC become activated,
proliferate, differentiate and eventually fuse into myo-
tubes that mature into myofibers [2]. The process of skel-
etal muscle regeneration is influenced by the nature of
injury (e.g., traumatic, chemical, ischemic), the composi-
tion of the extracellular matrix, the availability of growth
factors produced by inflammatory cells, vascular cells, and
motor neurons [3]. SC have a smaller nuclear size com-
pared with the adjacent nucleus of the myotube, and an
increased amount of nuclear heterochromatin compared
with that of the myonucleus [4]. Quiescent SC show little
transcriptional activity. Following activation, they appear
as a swelling on the myofiber with cytoplasmic processes
that extend from one or both poles of the cell. In adult
skeletal muscles, SC have been estimated to represent 1%
to 12% of cells in adult muscle. Activation of SC during
muscle regeneration requires upregulation of Myf5 and
MyoD, transcriptional activators of the myogenic regula-
tory factor family (MRF). Expression of these factors deter-
mines the transition of myogenic cells into myoblasts [3].
Expression of Pax3, Pax7, Sox15, MNF, cyclooxygenases
and other regulatory factors is also needed for SC activa-
tion [5-7]. Expression of the late MRFs (myogenin and
MRF4) precedes the production of muscle-specific pro-
teins (e.g., myosin heavy chain and muscle creatine
kinase). Expression of cytoskeletal (desmin) and surface
markers (M-cadherin, Syndecan-3 and -4, VCAM-1,
CD56, Glycoprotein Leu-19, CD34) as evidenced by
immunostaining is often exploited to follow myogenic
differentiation [3,8,9].
Over the past decade, experimental evidence has been
accumulating that the implant of cultured myoblasts can
represent an effective approach for repairing damaged
myocardium [1,10-12]. The functional benefit of intramy-
ocardially transplanted autologous or heterologous skele-
tal myoblasts has been established in different animal
models (rat, hamster, sheep) in which heart damage was
determined primarily by ischemia [13,14]. In humans,
autologous skeletal myoblast implantation has been prac-
ticed only in cases of left ventricular dysfunction pro-
duced by ischemic damage [15,16]. Recently, the implant
of autologous myoblasts has been proposed also in the
setting of dilated cardiomyopathy [17], urinary inconti-
nence [18,19], traumatic muscle damage [20], congenital
muscle disease [21]. As compared to other attractive cell
types, skeletal myoblasts have several clinically appealing
properties, including autologous origin, ease of procure-
ment, the ability of sufficient expansion in vitro, and the
ability of adequate differentiation upon in vivo implant.
The present study was initiated to determine if currently
available cell culture methods were suitable for obtaining
sufficient numbers of differentiated cells from muscle
biopsies of human donors aged over 40 years. The latter
condition was set since, with the exception of traumatic
injury, most of the above listed clinical conditions arise in
patients older than 50 years. In this context, it should be
borne in mind that, for cellular therapy, substantial num-
bers of implantable cells (i.e., ≥108) are needed within 1–
2 months of disease onset. In addition, cells expanded in
vitro need to be adequately differentiated along myogenic
lineages, free of demonstrable genetic alterations, and free
of contaminant macromolecules [22] and
microorganisms.
Methods
Cell donors and culture of skeletal muscle cells
Except where specified, chemical reagents, tissue culture
media, enzymes and human recombinant growth factors
were obtained from Sigma-Aldrich (St. Louis, MO). Plas-
ticware was obtained from Falcon (Becton Dickinson,
Milan, IT). Certified double-filtered fetal bovine serum
(FBS) produced in a TSE-free country was obtained from
HyClone (Logan, UT). Five patients of 41 to 91 years of
age gave informed consent for muscle biopsy in the course
of programmed heart or orthopedic surgery. Muscle biop-
sies of at least 1 cm in length were obtained from either
the abdominal rectus or femoral quadriceps. Specimens
were stripped of visible connective and fat tissue and
weighted. Each biopsy provided 0.6 to 1.9 g of muscle tis-
sue. The tissue was immersed in a small aliquot of Hepes-
buffered Ham's F12 medium supplemented with imi-
penem, vancomycin and amphotericin B (at the individ-
ual concentration of 10 mg/L), minced with sharp scissors
to obtain fragments of approximately 1 mm in diameter.
Enzymatic digestion was carried out in Ham's F12
medium containing 1.5 mg/ml Pronase E (nonspecific
protease from Streptomyces griseus) plus 0.03% EDTA at
37°C for 30 min with occasional shaking. After 5 min sed-
imentation at 1 g, the supernatant was collected and
stored at room temperature. Pelleted tissue debris were
subjected to 2–3 further cycles of the above digestion
process. Collected supernatants were filtered through a
100 µm nylon mesh (Becton Dickinson) and centrifuged
at 400 g for 8 min. The pellet was gently resuspended in
proliferation medium (PM). Viable cells were counted by
the trypan blue exclusion method. PM consisted of a 1:1
mixture of Dulbecco's modified Eagle's medium and F12
medium (DMEM/F12) containing L-glutamine (2 mM),
penicillin (50 units/ml), gentamicin (50 mg/L), andPage 2 of 10
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irradiated bovine fetuin (50 µg/ml), recombinant Hu EGF
(10 ng/ml), recombinant Hu bFGF (1 ng/ml), recom-
binant Hu insulin (10 µg/ml), dexamethasone (0.4 µg/
ml). Differentiation medium (DM) consisted of DMEM/
F12 supplemented with antibiotics, 10% FBS and recom-
binant Hu insulin (10 µg/ml). Cell suspensions obtained
from each biopsy were initially plated in two or more T-
75 flasks (i.e., ≥150 square cm) depending on the weight
of processed tissue. Cultures were incubated at 37°C in a
humidified atmosphere containing 5% CO2. Thirty-six hr
post-plating, adherent cells were gently washed and the
growth medium was changed. Cell passages were per-
formed by light treatment with trypsin-EDTA at the appro-
priate times indicated by microscopic observation (i.e.,
70–80% monolayer confluency). The first passage was
carried out 6 to 10 days post-plating. To minimize myo-
genic differentiation at higher myoblast density, subse-
quent passages were performed every 3–4 days.
Cell proliferation
Before each passage, cultures were examined with an
inverted microscope equipped with a digital camera.
Images were acquired with a 10× objective from 8–10 ran-
dom fields per culture and recorded. Counts of adherent
cells were obtained with a computerized image analysis
system (Image DB; Amplimedical, Mira, IT) and expressed
as number of cells per square millimeter. After trypsiniza-
tion, numbers of viable cells were counted by the trypan
blue exclusion method. The two methods gave concord-
ant results with an agreement of within 12%. Results are
expressed as total numbers of viable cells at different times
after culture initiation.
Immunostaining of muscle cell monolayers
Monolayers of cells that had been expanded for 35 to 40
days in PM were trypsinized and plated with PM in two-
well chamber slides (Nunc; PBI, Milan, IT). Two-three
days later, after gently removing the medium, cell monol-
ayers were fixed with cold 2.5% paraformaldehyde in
phosphate-buffered saline (PBS) for 15 min at 4°C,
washed with PBS, permeabilized with 0.1% Triton X-100
in PBS for 15 min, washed again with PBS and blocked for
60 min in TRIS-buffered saline (50 mM Tris, 0.15 M NaCl,
pH7.6) containing 0.2% BSA, 0.2% FBS, 0.01% Tween 20,
0.01% sodium azide [immunofluorescence assay (IFA)
buffer]. A mouse monoclonal antibody (mAb) to the
intermediate filament desmin (clone D33) that is
expressed during muscle development was obtained from
DakoCytomation (Milan, IT). mAbs to skeletal myosin
heavy chain type I slow (clone NOQ7.5.4D; specific for
slow myosin HC of skeletal and cardiac muscle), skeletal
myosin heavy chain type II fast (clone MY-32; specific for
fast myosin HC of skeletal but not cardiac or smooth mus-
cle), A-sarcomeric actin (clone C5C; specific for alpha-
skeletal and alpha-cardiac actin), A-sarcomeric actinin
(clone EA-53; specific for alpha-skeletal and alpha-cardiac
actinin localized at the Z band) were obtained from
Sigma-Aldrich. mAbs to spectrin (clone RBC2/3D5; spe-
cific for erythrocytes and muscle was used as a marker of
membrane integrity) and to the mid rod domain of dys-
trophin (clone Dy4/6D3; specific for the skeletal, cardiac
and smooth muscle forms of dystrophin that anchors the
cytoskeleton to the plasma membrane) were obtained
from Novocastra Laboratories (Newcastle upon Tyne,
UK). Cell monolayers were washed with IFA buffer and
incubated 60 min with primary antibody at room temper-
ature. After three washings with IFA buffer, slides were
incubated with FITC-labeled sheep anti-mouse IgG
(diluted 1:800 in blue Evans-containing buffer) for 60
min in the dark. After three further washings, slides were
mounted with an anti-fade containing medium (Vector
Laboratories, Burlingame, CA) and examined with a fluo-
rescence microscope (BX60; Olympus, Tokyo, Japan)
equipped with a digital camera (Nikon, Tokyo, Japan).
Cells showing cytoplasmic staining were counted at 200–
400× magnification. Results are expressed as mean per-
centage of positive cells over the number of examined
cells (at least 500 cells per slide were counted; experi-
ments were run in duplicate).
Cytogenetic analysis
When over 3 × 108 viable cells were obtained by in vitro
culture (i.e., over day-35 post-plating), an aliquot of each
culture was trypsinized and plated in two different cham-
ber slides. Cells were grown in PM, treated with colchicine
for 30 min, subjected to hypotonic treatment, fixed in
methanol:acetic acid (3:1), and processed according to
standard methods [23]. Fifty metaphases were analyzed
by QFQ-banding with an automated cytogenetics system
(Genikon; Nikon) following the rules of the International
System for Human Cytogenetic Nomenclature [24].
Screening of important human viruses
At the time of muscle biopsy, blood samples from each
patient were tested for HBV, HCV, and HIV markers by
conventional serology (DiaSorin, Saluggia, IT) and by
molecular tests (Cobas Amplicor; Roche Diagnostics,
Monza, IT). When over 3 × 108 viable cells had been
obtained by in vitro expansion, an aliquot of each culture
was tested by gene amplification methods for the presence
of important human viruses capable of causing persistent
infections. DNA was extracted from a frozen 0.5 ml aliq-
uot of PM containing 3 × 106 cells using a commercial kit
(QIAamp DNA blood mini kit; Qiagen, Milan, IT). PCR
was used to detect the genome of DNA human viruses
(CMV, EBV, HBV, parvovirus B19). Total RNA was
extracted from 3 × 106 cells by the guanidinium thiocy-
anate method (Life Technologies, Gaithersburg, MD).
cDNA was obtained from 2 µg of RNA with Mo-MLVPage 3 of 10
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amer primers (Clontech, Palo Alto, CA). RT-PCR was used
to detect HIV and HCV genomes. Routine Cobas Ampli-
cor methods were used for HBV, HCV and HIV. Published
primers were used to detect CMV, EBV, and parvovirus
B19 genomes [25]. The sensitivity of the employed meth-
ods was ≤100 genomic equivalents/reaction. CMV, EBV,
and parvovirus B19 amplicons were analyzed on 2% aga-
rose gel using ethidium bromide staining and were pho-
tographed on a transilluminator with the help of a digital
camera (Kodak Image Station 440CF; Celbio, Pero, IT).
Clinical samples positive for EBV, CMV, HBV, Parvovirus
B19, HCV, or HIV-1 were used as positive controls. Ampli-
fication of beta-globin (PCR) or GAPDH (RT-PCR) was
used to normalize the data.
Results
Growth of primary muscle cell cultures
As shown in Table 1, the age of muscle cell donors ranged
from 41 to 91 years. Tissue obtained from each biopsy
weighted from 0.6 to 1.9 g. The kinetics of cell growth
using the described culture conditions is illustrated in Fig-
ure 1. Thirty-six hr post-plating, the numbers of adherent
cells present in primary cultures of the 5 investigated
patients ranged from 0.16 to 1.58 millions. Peak cell
expansion occurred between day-42 and day-49 of cul-
ture. At these times, the total numbers of cultured viable
cells ranged from 446 to 1,739 millions. From days 42 to
49 post-plating, the total number of viable cells tended to
a plateau. Interestingly, a direct relationship existed
between the initial weight of bioptic tissue and the maxi-
mal numbers of in vitro expanded cells. This is apparent
by comparing tissue weights reported in Table 1 with the
kinetic data of Figure 1. The average number of cell popu-
lation doublings that was required to reach peak cell num-
bers, was 11.24 ± 0.73 (mean ± SD of 5 different primary
cultures). Calculated mean cell doubling times of investi-
gated primary cultures ranged from 3.56 to 4.60 days.
Overall, the mean cell doubling time was 3.98 ± 0.38 days
(mean ± SD, n = 5). From these data, no relationship was
apparent between the age of the cell donor and the mean
cell doubling time in culture (Table 1). Under the
employed culture conditions, the average fold increase of
the number of adherent cells counted on day-1.5 post-
plating was 2,490 (range 1,096- to 3,631-fold).
Morphologic aspects of primary human skeletal muscle
cultures are shown in Figure 2. The morphology of an
adherent SC is shown in Figure 2A (day-5 post-plating).
Figures 2B and 2C show cell monolayers cultured in PM
for 7 and 10 days, respectively. Experience with muscle
cultures from adult donors shows that changing the envi-
ronmental conditions of cultured myoblasts from PM to
DM is followed by cell fusion within a few days. Fusion
was only used to confirm the presence of myoblasts.
Table 1: Patients, weight of muscle biopsy, growth parameters of primary cultures.
Patient # (gender) Age (yr) Muscle biopsy site Weight of biopsy 
specimen (g)
Mean cell population 
doubling time (days)
Peak number of viable cells 
(×10-6) obtained at the indi-
cated time of culture (day)
1 (F) 91 Femoral quadriceps 1.0 3.88 1,148 (46)
2 (M) 61 Abdominal rectus 0.6 4.60 446 (49)
3 (M) 41 Abdominal rectus 1.3 3.56 562 (42)
4 (F)1 56 Abdominal rectus 1.9 4.15 1,739 (42)
5 (M) 75 Abdominal rectus 1.8 3.74 1,585 (49)
1. Patient showing HCV viremia at the time of muscle biopsy (53,000 genome equivalents/ml).
Growth kinetics of primary skeletal muscle cultured in prolif-eration mediumFigure 1
Growth kinetics of primary skeletal muscle cultured in prolif-
eration medium. At different time points, adherent cells were 
counted as described in the Materials and Methods section. 
Kinetics of cultures derived from five different patients are 
reported: (▲) patient #1; (■) patient #2; () patient #3; (❍) 
patient #4; (●) patient #5.
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myotubes are shown in Figure 2D.
Expression of differentiation markers by cultured muscle 
cells
The expression of selected skeletal muscle markers was
investigated by indirect immunofluorescence in fixed
monolayers of primary cultures expanded in vitro for 35
to 40 days. Table 2 shows the average reactivity of primary
cultures with different anti-muscle antibodies. The overall
positivity with the anti-desmin mAb (an intermediate fil-
ament marker that stains muscle cells, but not fibroblast-
oid cells) was 49.6% (range 40 to 53%), indicating that
approximately half of the in vitro-expanded cell popula-
tion was differentiated along the myogenic lineage. As
Morphologic aspects of primary human skeletal muscle cultured in vitroFigure 2
Morphologic aspects of primary human skeletal muscle cultured in vitro. Adherent satellite cell 5 days post-plating in prolifera-
tion medium (A; 40×). Semiconfluent monolayers of myoblasts cultured in proliferation medium for 7 (B; 20×) and 10 days (C; 
10×). Confluent myoblasts cultured in differentiation medium are in the process of fusing to form myotubes (D; 10×).
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myofibrillar proteins myosin type I slow and A-sarcomeric
actin produced banded filament images and stained
approximately one-third of cultured myoblasts. Myosin
type II fast (specific for skeletal but not cardiac muscle
cells) and A-sarcomeric actinin antibodies stained
filaments producing a more continuous pattern in 20–
30% of cells. The staining pattern produced by spectrin
and dystrophin antibodies was remarkably different since
was essentially limited to the periphery of cells and to
membrane patches in 30–40% of cells.
Karyotype of cultured muscle cells and screening of human 
viruses
Cytogenetic analysis and the search for human viruses
were performed in muscle cell cultures grown in PM for
35 to 40 days. Normal diploid karyotypes were obtained
from muscle cultures of all investigated patients. Figure 4
shows a representative metaphase and the normal male
karyotype of patient #5.
At the time when cultures were subjected to cytogenetic
analysis, samples were also processed for detecting
human viral pathogens. After DNA and RNA extraction,
PCR and RT-PCR methods were used for detecting the
genome of CMV, EBV, HBV, parvovirus B19, HIV, and
HCV. All cultures gave negative results with virus-specific
primers. Amplification for beta-globin (PCR), GAPDH
(RT-PCR), and virus-positive controls consistently gave
the expected results (data not shown). At the time of mus-
cle biopsy, RT-PCR had shown that patient #4 was HCV-
positive both in blood (53,000 genome equivalents/ml)
and in the muscle biopsy specimen. Interestingly, HCV
genome was not detected in cultured muscle cells
obtained from her biopsy at passage numbers 3, 6, and 9,
indicating that HCV failed to replicate in muscle cell
cultures.
Discussion
Currently available tissue culture techniques allow to
process skeletal muscle biopsies of patients aged over 40
as to obtain large numbers of isolated (not fused) cells
that are differentiated along myogenic lineages. Local
myogenesis, neoangiogenesis and homing of progenitor
cells from the bone marrow appear to contribute to the
repair of acutely infarcted myocardium [16,26]. Implanta-
tion of skeletal myoblasts [27,13,28], angiogenetic and
protective factors [29-31], hematopoietic stem cells [10]
has been associated with improved contractile function in
different animal models of myocardial infarction.
Implantation of skeletal myoblasts has also been pro-
posed for nonischemic cardiomyopathy [17]. Cautionary
notes on the use of bone-marrow derived stem cells for
heart regeneration derive from recent experiments in mice
in which autologous hematopoietic cells were not capable
of differentiating into cardiomyocytes and gave no func-
tional benefits over sham-treated control animals [32,33].
In humans, phase I clinical studies begin to demonstrate
the clinical benefits of autologous myoblast transplanta-
tion [22,12,34,14,15,11] and, to a minor extent, of autol-
ogous mesenchymal/hematopoietic cells [16,35,36].
In order to make clinical applications possible on a larger
scale, conditions for the reproducible and safe in vitro
expansion of human skeletal muscle need to be set. To
this end, five points are of particular relevance: 1) process-
ing of bioptic tissue as to obtain appropriate muscle stem
cells; 2) use of culture media free of non-human compo-
nents; 3) methods to evaluate the differentiation of cul-
tured cells along myogenic lineages; 4) methods to
evidence genetic alterations of cells to be implanted; 5)
methods to assure the absence of pathogenic microorgan-
isms (viruses causing persistent infections and TSE
agents). In the present study, several of these conditions
have been satisfied. Bioptic specimens have been proc-
essed with a widely available bacterial protease with
Table 2: Cytoplasmic markers expressed by primary cultures of skeletal muscle cells grown in vitro for 35 to 40 days1.
Monoclonal antibody Percentage of positive cells 
(mean ± SD)2
Fluorescence pattern
Desmin (skeletal muscle) 49.6 + 6.4 Cytoplasmic
Skeletal myosin type I slow heavy chain (skeletal and cardiac muscle) 33.4 + 3.9 Cytoplasmic filaments
A-sarcomeric actin (skeletal and cardiac muscle) 28.6 + 6.1 Cytoplasmic filaments
Skeletal myosin type II fast heavy chain (skeletal muscle, not cardiac) 29.4 + 6.2 Cytoplasmic filaments
A-sarcomeric actinin (skeletal and cardiac muscle) 19.0 + 3.7 Cytoplasmic filaments
Spectrin (erythrocyte and muscle) 32.6 + 7.5 Peripheral rim and membrane staining
Dystrophin (skeletal, cardiac and smooth muscle) 38.4 + 9.8 Peripheral rim and membrane staining
1. Indirect immunofluorescence assay on monolayers of cells grown using proliferation medium.
2. Positive cells in primary cultures derived from five different tissue donors.Page 6 of 10
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Journal of Translational Medicine 2005, 3:21 http://www.translational-medicine.com/content/3/1/21Indirect immunofluorescence to detect the expression of specific markers in primary muscle cells cultured for 35 to 40 days in proliferation medi mFigure 3
Indirect immunofluorescence to detect the expression of specific markers in primary muscle cells cultured for 35 to 40 days in 
proliferation medium. Staining of core myofibrillar proteins [myosin type I slow (A) and alpha-sarcomeric actin (B)] produced 
banded filament images. Staining of myosin type II fast (C) and alpha-sarcomeric actinin (D) produced a continuous filament pat-
tern. The staining pattern produced by spectrin (E) and dystrophin (F) was limited to the periphery of cells and to membrane 
patches. FITC labeling with Evans blue counterstaining. Original magnification, 60×.
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by fluorescence-activated sorting and/or antibodies has
not been attempted in this study, but seems promising
[37]. The medium employed has been supplemented with
carefully selected human recombinant growth factors.
Addition of FBS and fetuin remained however indispensa-
ble. Recently, media supplemented with autologous
human serum have been proposed and appear to be asso-
ciated with superior clinical results [22]. In particular, no
malignant arrhythmias were reported among 20 patients
and the post-infarctual LV ejection fraction was signifi-
cantly improved. Myogenic differentiation of human
myoblasts obtained with the proposed technique has
been comparable to what reported by others. Using
desmin as a cytoplastic marker, about 50% of cells cul-
tured from adult donors were differentiated along myo-
genic lineages. This result is comparable to what
previously reported using either the desmin marker [9] or
the CD56 surface marker [15]. Detailed characterization
showed that expanded muscle cell cultures maintained
the ability to express proteins proper of skeletal muscle
(myosin type I and II, actin, actinin, spectrin and dys-
trophin). Since the regulation of myosin heavy chain gene
expression is strongly regulated by transcriptional events
and by physical exercise [38], and since in old subjects
muscle fibers co-expressing myosin type I and myosin
type IIA are more frequent than in young subjects [39],
immunostaining of in vitro cultured cells should not be
expected to strictly reproduce what observed in tissue
sections.
Of particular interest for clinical applications is that
cytogenetic alterations were not detected in cultured cells
that had undergone at least 10 population doublings. This
was particularly reassuring since the investigated samples
were derived from adult/old donors and chromosomal
alterations are known to occur at an increased frequency
in tissues of adult/old peoples [40]. In future studies, the
new CGH technology could offer superior sensitivity for
detecting minor cytogenetic changes [41]. Finally, molec-
ular methods for common human viruses are widely
available and need to be employed in human clinical tri-
als to validate myoblast cultures prior to implant. Of
interest, is the chance observation that HCV failed to rep-
licate in one muscle culture derived from an HCV-infected
donor. This result is in agreement with experimental
observations showing that HCV has no effects on liver
myofibroblasts [42].
Conclusion
The results indicate that in about one month it is possible
to produce in vitro approximately one billion of
adequately differentiated skeletal muscle cells from
human donors, independently of age. Clinical experience
indicates that approximately 300 millions of autologous
skeletal muscle cells are sufficient for the cellular therapy
of infarcted heart [15,14]. Thus, an early intervention may
be possible by processing a muscle biopsy of about 2
grams. The proposed tissue culture methods may also rep-
resent a basis on which to envisage applications in the
urologic [18,19] and orthopedic fields [20,21].
List of abbreviations used
BFGF basic fibroblast growth factor
DM differentitation medium
DMEM/F12 Dulbecco's modified Eagle's medium plus
Ham's F12 medium
(A) Q banding of a metaphase from the primary muscle cell culture of patient #5 cultured for 35 days n p oliferation medium (orig nal magnification, 100×)Fig  4
(A) Q banding of a metaphase from the primary muscle cell 
culture of patient #5 cultured for 35 days in proliferation 
medium (original magnification, 100×). (B) Normal diploid 
male cell karyotype of the same patient.
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IFA immunofluorescence assay
PM proliferation medium
QFQ quinacrine chromosome banding
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